Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | CCR10 | P46092 | 15/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10445780 | 0.80 | CCR10 (0.36) | SLC6A2SLC6A4SLC6A3LMNAGLA | |
| SCHEMBL4970264 | 0.80 | TGFBR1 (0.34) | SLC6A2SLC6A4SLC6A3LMNAGLA | |
| SCHEMBL10504247 | 0.80 | CCR10 (0.36) | SLC6A2SLC6A4SLC6A3LMNAGLA | |
| SCHEMBL6332741 | 0.76 | HTR2C (0.45) | SLC6A2SLC6A4SLC6A3LMNACCR10 | |
| SCHEMBL27936480 | 0.74 | ALDH1A1 (0.47) | HDAC8HDAC6 | |
| SCHEMBL27993369 | 0.71 | LMNA (0.33) | SLC6A2SLC6A4SLC6A3LMNAGLA | |
| SCHEMBL27608334 | 0.68 | LMNA (0.35) | SLC6A2SLC6A4SLC6A3LMNAGLA | |
| SCHEMBL13692344 | 0.67 | DBH (0.47) | SLC6A2SLC6A4SLC6A3LMNAHDAC8 | |
| SCHEMBL27739596 | 0.67 | — | — | |
| SCHEMBL11491021 | 0.66 | CYP19A1 (0.36) | LMNAHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2246347-B1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARM CO LTD (CN) | 2016-09-28 | — | — | EP | disclosed |
| US-8415349-B2 | Dicycloazaalkane derivatives, preparation processes and medical uses thereof | Jiangsu Hansoh Pharmaceuticals Co., Ltd. (CN) | 2013-04-09 | — | — | US | disclosed |
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2013-01-10 | — | — | US | disclosed |
| US-8304411-B2 | Dicycloazaalkane derivates, preparation processes and medical uses thereof | JIANGSU HANSOH PHARMACEUTICAL CO., LTD. (CN) | 2012-11-06 | — | — | US | disclosed |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2010-12-09 | — | — | US | disclosed |
| EP-2246347-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2010-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012705-A1 | DICYCLOAZAALKANE DERIVATIVES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | SLC6A2 2681/4885SLC6A4 970/4885SLC6A3 915/4885 |
| US-20100311747-A1 | DICYCLOAZAALKANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | DPP4, DPP8, DPP7 | SLC6A2 2976/4885SLC6A4 1039/4885SLC6A3 936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.